Karyopharm Therapeutics Inc. Uncategorized Contracts & Agreements
33 Contracts & Agreements
- Offer Letter, dated as of April 4, 2022, between the Registrant and Reshma Rangwala (Filed With SEC on May 8, 2024)
- Side Letter to Offer Letter, dated October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on May 5, 2022)
- Omnibus Amendment to Transaction Documents, dated as of June 23, 2021, by and among the Company, Karyopharm Europe GmbH, Karyopharm Therapeutics (Bermuda) Ltd., HealthCare Royalty... (Filed With SEC on June 24, 2021)
- Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on May 3, 2021)
- Amended and Restated Letter Agreement, dated as of April 28, 2021, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on May 3, 2021)
- Offer Letter, dated as of April 28, 2021, between the Company and Richard Paulson (Filed With SEC on May 3, 2021)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 24, 2021)
- Letter Agreement, dated as of October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on November 2, 2020)
- Letter Agreement, dated as of August 31, 2020, between the Company and Michael Mason (Filed With SEC on August 31, 2020)
- Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Christopher B. Primiano (Filed With SEC on August 31, 2020)
- Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on August 31, 2020)
- Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on August 31, 2020)
- Amendment No. 1 to the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated May 5, 2020 (Filed With SEC on May 5, 2020)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)
- Offer Letter, dated February 3, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
- Open Market Sale AgreementSM, dated August 17, 2018, by and between Karyopharm Therapeutics Inc. and Jefferies LLC (Filed With SEC on August 17, 2018)
- Offer Letter, dated June 7, 2018, by and between the Registrant and Anand Varadan (Filed With SEC on August 7, 2018)
- Offer Letter, dated September 9, 2017, between the Company and Michael Falvey (Filed With SEC on September 12, 2017)
- First Amendment to Letter Agreement (Filed With SEC on March 16, 2017)
- 1. Nachtrag zum Geschäftsführer- Anstellungsvertrag (Filed With SEC on November 9, 2015)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on November 9, 2015)
- Vereinbarung über die Änderung eines Geschäftsführer-Anstellungsvertrags (Filed With SEC on March 13, 2015)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on March 13, 2015)
- Page 2 of 6 (Filed With SEC on March 13, 2015)
- Geschäftsführer-Anstellungsvertrag zwischen (Filed With SEC on March 13, 2015)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on January 23, 2015)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on January 23, 2015)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on January 23, 2015)
- [Signatures appear on following page] (Filed With SEC on August 8, 2014)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on March 21, 2014)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on October 28, 2013)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on October 28, 2013)
- KARYOPHARM THERAPEUTICS INC. (Filed With SEC on October 28, 2013)
